TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06680830: A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Sponsor: Neuron23 Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,987,600

Rescue Site Savings

+$1,978,800

Unlock Full NCT06680830 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06680830 Rescue Dossier →